Joyeeta Roy
Overview
Explore the profile of Joyeeta Roy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rej R, Rao Allu S, Roy J, Acharyya R, Kiran I, Addepalli Y, et al.
Pharmaceuticals (Basel)
. 2024 Apr;
17(4).
PMID: 38675453
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to...
2.
Rej R, Roy J, Rao Allu S
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339303
The hormone receptor-positive (HR+) type is the most frequently identified subtype of breast cancer. HR+ breast cancer has a more positive prognosis when compared to other subtypes, such as human...
3.
Guevremont D, Roy J, Cutfield N, Williams J
Sci Rep
. 2023 Sep;
13(1):16272.
PMID: 37770507
Current clinical tests for Parkinson's disease (PD) provide insufficient diagnostic accuracy leading to an urgent need for improved diagnostic biomarkers. As microRNAs (miRNAs) are promising biomarkers of various diseases, including...
4.
Xu Y, Xue D, Kyani A, Bankhead 3rd A, Roy J, Ljungman M, et al.
ACS Pharmacol Transl Sci
. 2023 Aug;
6(8):1164-1181.
PMID: 37588763
Pancreatic cancer cells adapt to nutrient-scarce metabolic conditions by increasing their oxidative phosphorylation reserve to survive. Here, we present a first-in-class small-molecule NDUFS7 antagonist that inhibits oxidative phosphorylation (OXPHOS) for...
5.
Roy J, Kyani A, Hanafi M, Xu Y, Takyi-Williams J, Sun D, et al.
J Med Chem
. 2023 Jan;
66(3):1990-2019.
PMID: 36692906
Sigma 2 receptor (σ2R) is overexpressed in select cancers and is regarded as a biomarker for tumor proliferation. σ2R ligands are emerging as promising theranostics for cancer and neurodegenerative diseases....
6.
Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, et al.
J Med Chem
. 2022 Feb;
65(4):3404-3419.
PMID: 35167303
Targeting oxidative phosphorylation (OXPHOS) complexes is an emerging strategy to disrupt the metabolism of select cancer subtypes and to overcome resistance to targeted therapies. Here, we describe our lead optimization...
7.
Xue D, Xu Y, Kyani A, Roy J, Dai L, Sun D, et al.
J Med Chem
. 2022 Jan;
65(1):343-368.
PMID: 34982568
Inhibition of oxidative phosphorylation (OXPHOS) is a promising therapeutic strategy for select cancers that are dependent on aerobic metabolism. Here, we report the discovery, optimization, and structure-activity relationship (SAR) study...
8.
Brzegowy K, Pekala P, Zarzecki M, Pekala J, Roy J, Aziz H, et al.
World Neurosurg
. 2019 Sep;
133:e401-e411.
PMID: 31536812
Background: The primitive trigeminal artery (PTA) is the most common and the largest persistent carotid-basilar anastomosis. Primitive trigeminal artery variants (PTAVs) are anastomoses between the internal carotid artery and cerebellar...
9.
Keet K, Roy J, Henry B
Clin Anat
. 2019 Mar;
32(5):697-698.
PMID: 30875136
Sex- and gender-based differences need to be considered in evidence-based medical research as there are anatomical and physiological differences between males and females. Females are underrepresented in studies, with results...
10.
Shahin M, Roy J, Hanafi M, Wang D, Luesakul U, Chai Y, et al.
Eur J Med Chem
. 2018 Jun;
155:516-530.
PMID: 29908444
No new and effective treatments have been approved for the treatment of esophageal squamous cell carcinoma (ESCC) in the past decade. Cisplatin and 5-fluoruracil are the most commonly used drugs...